about
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report.Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma.Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract CancerResults of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activationLong-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer.Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer.Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma.The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity.Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.Pseudoprogression in glioblastoma patients: the impact of extent of resection.¹⁸F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis.Prognostic significance of standardized uptake value on preoperative ¹⁸F-FDG PET/CT in patients with ampullary adenocarcinoma.Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients.In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas.Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of VaterCapecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Randomized, Phase Three, Non-Inferiority TrialPrognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single instituteThe combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
P50
Q27853079-2CAD1B37-87EE-485E-8A0F-67C3A2F50B37Q30417878-F2F92E96-22B0-4ECB-8FC2-AED80CF02071Q33375594-AD5192AC-33C9-41B2-8971-29C9326AE86DQ33382051-32622734-7335-41B2-A621-6D17362A9D5AQ34384273-986F7836-3911-4259-88E0-0B4F2C98F40FQ35150642-B0627C4B-9C94-45BC-8840-673E95500FCEQ36187013-8089BF8C-E9A2-428D-9E55-F462F0810257Q37206411-F1975DD9-E14B-45A4-B2AC-23F1B1A636CFQ37259570-3A846A1C-155C-45AF-82A4-BEF46E5ABDCFQ37716633-57E186C7-2AAB-4E4E-B762-3DABF4083E33Q38401359-2A6CDD71-FA4E-4F97-942B-9303A0BD7408Q38489488-6B4B44A9-CA0E-48F3-B9E4-9C382D43B598Q38490343-47A86D4E-9BF4-4C7E-984F-1852F3E5BDFCQ38811077-8A6A4B5A-884A-4550-9A41-3E9C6E74EC5CQ38917103-E5A32D15-AE6F-4771-869F-A29BED919A7DQ39051743-29CA537A-90CA-4321-A03A-9C0AD334C76CQ39093972-8EA07B5D-B815-48F0-8970-829CD719C235Q39863380-64B19BAD-914F-4C64-907C-2EA434734F56Q40100642-FEF9C9E6-16FA-4DBA-807D-305D6A4ADA45Q40181533-E8185B53-D569-46AD-8355-59945C38E5E3Q44061094-AB3E33CA-C665-4191-805D-261CC1F255BFQ44868875-00143790-AF51-4FD7-AFEE-1053162B822DQ46835612-A6428652-3D5D-4A93-80D7-67427517F5F0Q47337999-34A6A326-044A-44E4-9560-15B8C39E5BCAQ48208260-40D28CDB-BD57-4C02-90C7-839D744F4981Q51567050-C9C7B68D-1BEA-4841-9932-3E64F7B87D7DQ51749846-72418B1B-E7BC-4544-B5FE-42A730902ADFQ52145872-82BB82F0-A1F7-416A-A3BA-98470DC1EFCAQ53037534-4BDF92B4-2FE4-42AB-A0DA-D65E457BEC8FQ53051639-8507B4F1-4EC3-423F-AE9B-E3369DCCA58DQ53071094-4C7AC2BF-007D-459C-88C3-8FFD2405629DQ53214416-17ADE404-6842-4F27-9736-2C23065BF33AQ53393758-E232BB83-D3F9-4B59-9F20-AC84B06DABA2Q53394103-C5D6D652-9F8F-4BC4-98D8-CF5B081B794BQ53433483-B5F23CD8-E098-42D8-ADCB-72C6194631F0Q54319381-B104ED9C-9259-4DDC-AB6A-962AE23B162EQ64051109-81DCC5C8-8C96-4B1E-B7E3-35D38EFEB56CQ64115686-745CC43F-B502-4C27-842E-E5E3DEE11204Q79456937-52433892-DFA6-4C3E-9980-AC94CBE7C9C7Q79999473-00DD40C7-DC1C-4138-AFBD-A8B41000FC9F
P50
description
investigador
@es
researcher
@en
name
Hye Jin Choi
@en
Hye Jin Choi
@nl
type
label
Hye Jin Choi
@en
Hye Jin Choi
@nl
prefLabel
Hye Jin Choi
@en
Hye Jin Choi
@nl
P31
P496
0000-0001-5917-1400